Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT06832228
Status
Recruiting
Apply to this trial

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)

Key Dates

Start date
Sep 1, 2024
Status verified
Jun 2024
Primary completion
Sep 1, 2025
Completion
Sep 1, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: pomalidomide combination with rituximab and Anti-PD-1 Antibody
    All patients will receive the PPR regimen (a total of 4-6 cycles, 28 days for each cycle): * pomalidomide: 4 mg, orally, once daily from Day 1 to Day 21. * Rituximab: 375 mg/m², administered on Day 1. * PD-1: 200 mg, administered on Days 1. Patients who achieved PR or CR after 6 cycles were treated with maintenance therapy at the investigator's discretion (1-2 years).

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: 28days after the end of treatment ]

Central Contacts

Related Studies